二、离任对公司的影响 证券代码：600713 证券简称：南京医药 公告编号：ls2025-130 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于公司董事离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 南京医药股份有限公司（以下简称"公司"）董事会收到非独立董事陆志虹 先生提交的书面辞职报告，陆志虹先生申请辞去公司第十届董事会董事、董事会 审计与风险控制委员会、薪酬与绩效考核委员会委员职务，辞去上述职务后不在 公司担任任何职务。 | 姓名 | 离任职务 | 离任时间 | | 原定任期到 期日 | | 离任原因 | 是否继续在 上市公司及 | 具体职务 （如适 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 其控股子公 司任职 | 用） | 公开承诺 | | | 董事；董事会审计 与风险控制委员 | 2025 年 10 | 月 | 2028 ...

Group 1 - The company Nanjing Pharmaceutical announced on October 17 that non-independent director Lu Zhihong submitted a written resignation report due to other work commitments [1] - Lu Zhihong applied to resign from his positions on the company's 10th Board of Directors, as well as the Audit and Risk Control Committee and the Compensation and Performance Assessment Committee [1] - After resigning from these positions, Lu Zhihong will not hold any position within the company [1] Group 2 - Lin Yuan responded firmly to the market's concerns about losses during the bull market, stating "I am still here!" and emphasized that he will continue to invest [1] - He maintains that liquor stocks represent "pleasure demand" and expressed concerns about technology stocks, indicating they cause him sleepless nights [1]

Core Viewpoint - Nanjing Pharmaceutical announced the resignation of director Lu Zhihong due to other work commitments, effective from October 17, 2025 [1] Group 1 - Lu Zhihong submitted a written resignation report to the company’s board, which will take effect upon delivery [1] - The board expressed gratitude for Lu Zhihong's contributions during his tenure [1] - The company will promptly complete the appointment of a new director in accordance with relevant regulations [1]

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. is terminating the public listing of its subsidiary, Liaoning Kangda Color Printing Packaging Co., Ltd.'s assets due to a lack of interested buyers after one year of offering the assets for sale [1][2]. Group 1: Asset Disposal Decision - On August 28, 2024, the company's board approved the public listing of certain assets from Liaoning Kangda Color Printing Packaging Co., Ltd. to enhance operational quality and profitability [1]. - The assets include 24,763.11 square meters of buildings, 46,872.11 square meters of land use rights, and 12 structures, with an assessed value of 37.35 million yuan [1]. Group 2: Asset Listing Progress - From October 12, 2024, to October 12, 2025, the assets were publicly listed on the Shenyang United Property Rights Exchange, but no interested buyers were found by the deadline [2]. - On October 13, 2025, the company received a confirmation from the exchange regarding the lack of interest in the assets, leading to the termination of the listing [2].

Core Viewpoint - Nanjing Pharmaceutical announced a significant reduction in its convertible bonds by its controlling shareholder, indicating a strategic shift in investment or liquidity management [1] Group 1: Company Actions - The controlling shareholder, Nanjing New Industry Investment Group Co., Ltd., notified that it has reduced its holdings of "Nanjing Pharmaceutical Convertible Bonds" by 1,108,000 units [1] - This reduction represents 10.25% of the total issuance of the convertible bonds [1]

一、控股股东配售可转债情况 经中国证券监督管理委员会《关于同意南京医药股份有限公司向不特定对象发 行可转换公司债券注册的批复》（证监许可〔2024〕1736 号）核准，公司向不特 定对象发行可转债 10,814,910 张，每张面值为人民币 100 元（人民币，下同），发 行总额 108,149.10 万元。本次发行的可转债存续期限为自发行之日起六年（2024 年 12 月 25 日至 2030 年 12 月 24 日）。 证券代码：600713 证券简称：南京医药 编号：ls2025-129 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于控股股东减持公司可转换公司债券的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于近日收到控股股东南京新工投 资集团有限责任公司（以下简称"新工投资集团"）的通知，新工投资集团已于 2025 年 9 月 16 日至 2025 年 10 月 14 日期间通过上海证券交易所（以下简称"上交 所"）系统减持其持有的部分公司可 ...

Group 1 - The company Nanjing Pharmaceutical (600713.SH) has received a notification from New Investment Group regarding a reduction in holdings [1] - The reduction period for the convertible bonds occurred from September 16, 2025, to October 14, 2025 [1] - New Investment Group has cumulatively reduced its holdings of "Nanjing Pharmaceutical Convertible Bonds" by 1.108 million units, which accounts for 10.25% of the total issuance of the convertible bonds [1]

Core Points - New Industrial Investment Group plans to reduce its holdings of "Nanjing Pharmaceutical Convertible Bonds" by 1.108 million units from September 16 to October 14, 2025, which accounts for 10.25% of the total issuance [1] - After the reduction, the group will hold 2.5807 million units, representing 23.86% of the total [1] - Previously, the group had already reduced its holdings by 1.0815 million units from September 1 to September 15, 2025, which accounted for 10.00% of the total [1]

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. announced the termination of the public listing for the disposal of assets from its wholly-owned subsidiary, Liaoning Kangda Color Printing and Packaging Co., Ltd., due to the lack of interested buyers after one year of open bidding [1][2]. Group 1: Asset Disposal Decision - On August 28, 2024, the company's board approved the public listing for the disposal of certain assets, including land use rights and buildings, with a minimum listing price based on an asset evaluation of 37.35 million yuan [1]. - The assets include 24,763.11 square meters of buildings, 46,872.11 square meters of land use rights, and 12 structures, all located in Shenyang Economic and Technological Development Zone [1]. Group 2: Asset Listing Progress - From October 12, 2024, to October 12, 2025, the assets were publicly listed on the Shenyang United Property Rights Exchange, but no interested buyers were found by the deadline [2]. - On October 13, 2025, the company received a confirmation letter from the exchange stating that the asset listing had ended without any bids [2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为盘活内部闲置资产，进一步聚焦核心资源提升公司整体运营质量和盈利水平， 南京医药股份有限公司（以下简称"公司"）全资子公司辽宁康大彩印包装有限公 司（以下简称"康大彩印"）公开挂牌处置其拥有的部分土地使用权及房屋建筑物 等。截止2025年10月12日，仍未征集到意向受让方，本次挂牌自行终止。现将具体 情况公告如下： 证券代码：600713 证券简称：南京医药 编号：ls2025-128 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于全资子公司辽宁康大彩印包装有限公司公开挂牌 处置相关资产的进展公告 三、风险提示 公司将根据该事项具体情况另行确定资产处置方案并及时履行信息披露义务。 敬请广大投资者注意投资风险。 特此公告 南京医药股份有限公司董事会 2025 年 10 月 15 日 1 一、康大彩印资产挂牌决策情况 2024年8月28日，公司第九届董事会第八次会议审议通过《关于拟公开挂牌处 置辽宁康大彩印包装有限公司相关资产的议案》。董事会同意康大彩印以不低 ...